NCAM1 and rectal cancer: This study validates the positive impact of nCRT combined with immunotherapy on the immune microenvironment of rectal cancer, particularly through increased infiltration of CD4+, CD8+ T cells, and CD56+ NK cells, which enhances the antitumor immune response.